Overview

Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China

Status:
Active, not recruiting

Trial end date:
2024-12-30

Target enrollment:

Participant gender:

Summary

To evaluate safety and efficacy of everolimus (Afinitor®) in Chinese adult patients with local advanced or metastatic, well differentiated progressive pancreatic neuroendocrine tumors.

Phase:

Phase 4

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

Everolimus
Sirolimus